Target intelligence / Profile preview

26S proteasome non-ATPase regulatory subunit 10 (Gankyrin)

Target
Gankyrin
Molecular classification
Proteasome subunit, Oncoprotein, Non-ATPase regulatory subunit, Ankyrin repeat protein, Chaperone for proteasome assembly
01

Overview

Gankyrin is a small, structurally-repeat protein consisting of seven ankyrin repeats that functions as a non-ATPase subunit of the 19S regulatory cap of the 26S proteasome. It plays critical roles in cell cycle progression and oncogenesis by promoting the degradation of key tumor suppressors (p53 and pRb) and by affecting the activity of CDK4 and MDM2, contributing to cellular transformation and proliferation. Gankyrin interacts with several other proteins through its conserved ankyrin repeat surface, acting as a hub for protein-protein interactions critical for both proteasome assembly and cancer cell signaling. Its overexpression is highly correlated with cancer progression and poor prognosis, making it an attractive target for anti-cancer drug development and a clinical biomarker for aggressive tumors.

Other names
PSMD10p28GankyrinProteasome subunit p28
02

Mechanism of action

Inhibitors may block gankyrin’s interactions with CDK4, MDM2, and proteasome machinery, which in turn can stabilize tumor suppressors p53 and pRb

03

Biological functions

Regulation of cell cycleProtein-protein interaction facilitatorDegradation of tumor suppressors (p53, pRb)Negative regulation of apoptosisChaperone for proteasome assembly
04

Disease associations

Cancer (strong evidence for hepatocellular carcinoma and other solid tumors)Cell proliferation/proliferative diseases
05

Safety considerations

As gankyrin is a core proteasome subunit, complete inhibition may interfere with normal proteasome functions, possibly leading to unintended proteostasis and cell cycle disruption
06

Interacting drugs

cjoc42
07

Biomarkers

Gankyrin (PSMD10/p28) protein expression level is used as a biomarker for poor prognosis and aggressive cancer phenotype, especially in hepatocellular carcinoma

Beyond the preview

Go deeper on 26S proteasome non-ATPase regulatory subunit 10 (Gankyrin).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 10 (Gankyrin).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call